|
Sep 4
|
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
|
|
Sep 3
|
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
|
Jun 12
|
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
|
|
Jan 11
|
Voting Rights and Shares Capital of the Company
|
|
Dec 4
|
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
|
|
Oct 23
|
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
|